Scarica l'app Stockscreener
9.17
5.95%
-0.58
Dopo l'orario di chiusura:
9.22
0.05
+0.55%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVAX Giù?
Forum
Previsione
Frazionamento azionario
Novavax Inc Borsa (NVAX) Ultime notizie
Novavax (NASDAQ:NVAX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Decliners Report: Is Novavax Inc a play on infrastructure spendingRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals - Yahoo Finance
Novavax grants license for use of Matrix-M adjuvant to Pfizer - MSN
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus - Sahm
Key facts: Novavax signs $30M deal with Pfizer; shares rise 19.7% - TradingView — Track All Markets
Novavax, Inc.'s (NASDAQ:NVAX) Price Is Right But Growth Is Lacking After Shares Rocket 46% - 富途资讯
Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality - marketscreener.com
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal - Intellectia AI
MRNA vs. NVAX: Which vaccine stock is Wall Street more bullish on right now? - MSN
The Bull Case For Pfizer (PFE) Could Change Following Novavax Matrix-M Adjuvant Licensing DealLearn Why - simplywall.st
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? - Stocktwits
Why Are Novavax (NVAX) Shares Soaring Today - The Globe and Mail
Novavax Strikes Major Deal with Pfizer, Surge in Stock Likely - StocksToTrade
Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX) - MarketBeat
Novavax Strikes $500M Licensing Deal with Pfizer for Matrix-M Technology - timothysykes.com
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M (NASDAQ:NVAX) - Seeking Alpha
Pfizer and Novavax ink $530m vaccine delivery licensing deal - Yahoo Finance
Novavax licenses Matrix-M adjuvant to Pfizer in deal worth up to $530 million By Investing.com - Investing.com South Africa
Novavax inks license agreement with Pfizer - The Pharma Letter
Novavax signs licensing agreement with Pfizer for vaccine development - Reuters
Assessing Novavax (NVAX) Valuation After Pfizer Matrix M Licensing Deal - Yahoo Finance
Novavax (NASDAQ:NVAX) Stock Price Up 8%Still a Buy? - MarketBeat
Novavax Licenses Rights to Key Vaccine Component to Pfizer - The Wall Street Journal
Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story - simplywall.st
Novavax’s Adjuvant Licensing Strategy Continues With Pfizer Pact - Citeline News & Insights
BTIG Reiterates Buy Rating for NVAX with $19 Price Target | NVAX Stock News - GuruFocus
Novavax licenses Matrix-M adjuvant to Pfizer in deal worth up to $530 million - Investing.com Canada
Novavax Pops on Pfizer Licensing Deal - GuruFocus
Novavax's (NVAX) Buy Rating Reiterated at BTIG Research - MarketBeat
Novavax Stock Pops After Pfizer Licensing Agreement - Schaeffer's Investment Research
Novavax strikes deal with Pfizer for immune-boosting tech worth up to $530M - The Business Journals
Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant - marketscreener.com
Novavax, Inc. Enters into A License and Option Agreement with Pfizer Inc - marketscreener.com
Novavax (NVAX) Surges on Licensing Deal with Pfizer - GuruFocus
Novavax rises on licensing deal with Pfizer (NVAX:NASDAQ) - Seeking Alpha
Investor Outlook: Novavax, Inc. (NVAX) Shows Potential 59.66% Upside Despite Challenges - DirectorsTalk Interviews
Novavax Announces Entering into a License Agreement with Pfizer - PR Newswire
Novavax enters license agreement with Pfizer for vaccine development - marketscreener.com
Novavax Enters $30M Licensing Agreement with Pfizer for Matrix-M® - Intellectia AI
Novavax Signs License and Option Agreement With Pfizer - TradingView
2.92%
2.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):